Anti-Human MCAM/CD146 Reference Antibody (JM1-24-3, RUO) (HW484046)

Name: Anti-Human MCAM/CD146 Reference Antibody (JM1-24-3, RUO)
Brand: abinScience
SKU: HW484046
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HW484046
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	JM1-24-3
Biological activity	JM1-24-3 (0.001-10 ug/mL) binds dose-dependently to live A375, A2058, and WM266-4 melanoma cells, with significantly stronger binding to highly metastatic A2058 and WM266-4 cells than to low metastatic A375 cells [1]. JM1-24-3 (0.001-10 ug/mL) binds dose-dependently to A375, A2058, and WM266-4 melanoma cell lysates, with significantly stronger binding to highly metastatic A2058 cell lysates than to WM266-4 or low metastatic A375 cell lysates [1]. JM1-24-3 binds to recombinant MUC18 with a high affinity (K D = 1.60E-09) [1]. JM1-24-3 (0.001-1 ug/mL) binding to WM266-4 melanoma cells is partially dependent on N-linked glycosylation of MUC18, as tunicamycin treatment (3.0 ug/mL; 24 h) reduces binding by 40.7% [1]. JM1-24-3 (1 h, 6 h for RPPA; 0.5-24 h for WB) binding to MUC18 on WM266-4 melanoma cells modulates downstream signaling pathways, including time-dependent reduction of p-AKT (Ser473) and p-mTOR (Ser2448) phosphorylation, and alters expression of key cancer-associated proteins [1]. JM1-24-3 (150 ug/mL; 7 days) inhibits proliferation of A375, A2058, and WM266-4 melanoma cells by 52%, 76%, and 46% respectively after 7 days of incubation [1]. JM1-24-3 (150 ug/mL; 24 h) inhibits migration of WM266-4 melanoma cells by 58% after 24 h of incubation [1]. JM1-24-3 (150 ug/mL) inhibits invasion of WM266-4 melanoma cells by 52% [1]. Cell Proliferation Assay [1] Cell Line: A375, A2058, WM266-4 Concentration: 150 ug/mL Incubation Time: 7 days Result: Significantly inhibited proliferation of all three cell lines: A375 by 52%, A2058 by 76%, and WM266-4 by 46% (p < 0.01 for all) compared to irrelevant mAb treatment. Cell Migration Assay [1] Cell Line: WM266-4 Concentration: 150 ug/mL Incubation Time: 24 h Result: Significantly reduced WM266-4 cell migration by 58% (p < 0.01) compared to irrelevant mAb treatment. JM1-24-3 (6 mg/kg; i.p.; twice weekly; for 45 days) significantly reduces the volume of subcutaneous melanoma xenografts, with no observed toxicity [1].
Expression system	Mammalian cells
Clonality	Monoclonal
Target	CD146, Melanoma cell adhesion molecule, S-endo 1 endothelial-associated antigen, Melanoma-associated antigen A32, MUC18, MCAM, Melanoma-associated antigen MUC18, Cell surface glycoprotein MUC18, Cell surface glycoprotein P1H12
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P43121
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	JM1-24-3
Background	Cell surface glycoprotein MUC18 (CD146/MCAM) is a ~71 kDa protein. Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as a surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration.
References	1. Feng R, et al. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. J Exp Clin Cancer Res. 2020;39(1):273. Published 2020 Dec 5. [HW484046] 2. Zhang F, et al. MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma. J Transl Med. 2025;23(1):473. Published 2025 Apr 24. [HW484046]
Note	For research use only. Not suitable for clinical or therapeutic use.